In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenem-resistant acinetobacter baumannii

Microbial Drug Resistance

Volumn 18, Issue 6, 2012, Pages 574-577

  Pei, Guangsheng ^a   Mao, Yimin ^a   Sun, Yuxia ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; CEFTAZIDIME; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; RIFAMPICIN; SULPERAZON; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANALYTIC METHOD; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; CHECKERBOARD METHOD; CHINA; CONTROLLED STUDY; DRUG POTENTIATION; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CEFOPERAZONE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SULBACTAM;

ACINETOBACTER BAUMANNII;

EID: 84869400351     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2012.0076     Document Type: Article

References (18)

1. Bishburg, E., and K. Bishburg. 2009. Minocycline-an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int. J. Antimicrob. Agents 34:395-401.
2. Coelho, J.M., J.F. Turton, M.E. Kaufmann, J. Glover, N. Woodford, M. Warner, M.F. Palepou, R. Pike, T.L. Pitt, B.C. Patel, and D.M. Livermore. 2006. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J. Clin.Microbiol. 44:3623-3627.
3. Fierobe, L., J.C. Lucet, D. Decre, C. Muller-Serieys, A. Deleuze, M.L. Joly-Guillou, J. Mantz, and J.M. Desmonts. 2001. An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect. Control Hosp. Epidemiol. 22:35-40.
4. Halstead, D.C., J. Abid, and M.J. Dowzicky. 2007. Antimicrobial susceptibility among Acinetobacter calcoaceticusbaumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J. Infect. 55:49-57.
5. Hawley, J.S., C.K. Murray, M.E. Griffith, M.L. McElmeel, L.C. Fulcher, D.R. Hospenthal, and J.H. Jorgensen. 2007. Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob. Agents Chemother. 51: 376-378.
6. Hujer, K.M., A.M. Hujer, E.A. Hulten, S. Bajaksouzian, J.M. Adams, C.J. Donskey, D.J. Ecker, C. Massire, M.W. Eshoo, R. Sampath, J.M. Thomson, P.N. Rather, D.W. Craft, J.T. Fishbain, A.J. Ewell, M.R. Jacobs, D.L. Paterson, and R.A. Bonomo. 2006. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob. Agents Chemother. 50: 4114-4123.
7. Clinical and Laboratory Standards Institute. 2010. Performance Standards for Antimicrobial Susceptibility Testing; twentieth informational supplement, pp. 54-55.
8. Kempf, M., and J.M. Rolain. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int. J. Antimicrob. Agents 39: 105-114.
9. Kiffer, C.R., J.L. Sampaio, S. Sinto, C.P. Oplustil, P.C. Koga, A.C. Arruda, P.J. Turner, and C. Mendes. 2005. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 52:317-322.
10. Landman, D., J.M. Quale, D. Mayorga, A. Adedeji, K. Vangala, J. Ravishankar, C. Flores, and S. Brooks. 2002. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch. Intern. Med. 162: 1515-1520.
11. Liang, W., X.F. Liu, J. Huang, D.M. Zhu, J. Li, and J. Zhang. Activities of colistin-and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect. Dis. 11:109.
12. Maragakis, L.L., and T.M. Perl. 2008. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46:1254-1263.
13. Motaouakkil, S., B. Charra, A. Hachimi, H. Nejmi, A. Benslama, N. Elmdaghri, H. Belabbes, and M. Benbachir. 2006. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J. Infect. 53:274-278.
14. Peleg, A.Y., H. Seifert, and D.L. Paterson. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
15. Tan, T.Y., L.S. Ng, E. Tan, and G. Huang. 2007. In vitro effect of minocycline and colistin combinations on imipenemresistant Acinetobacter baumannii clinical isolates. J. Antimicrob. Chemother. 60:421-423.
16. Tarchini, G. 2009. Nephrotoxicity associated with intravenous colistin. Clin. Infect. Dis. 49:1773; author reply 1773.
17. Timurkaynak, F., F. Can, O.K. Azap, M. Demirbilek, H. Arslan, and S.O. Karaman. 2006. In vitro activities of nontraditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents 27:224-228.
18. Yamaguchi, K., D. Mathai, D.J. Biedenbach, M.T. Lewis, A.C. Gales, and R.N. Jones. 1999. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group. Diagn. Microbiol. Infect. Dis. 34: 123-134.